1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Bradykinesia in 14 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Morphine has been found to elevate dopamine levels, which indicates a potential therapeutic effect in PD treatment that has not been investigated previously." | 5.40 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. ( Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S, 2014) |
| " The extract at both the doses displayed a significant reduction in postural flexion, moderate decrease in tremor, muscular rigidity and postural immobility scores but do not exhibit significant lowering of hypokinesia score in reserpine induced Parkinsonian model." | 4.12 | Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. ( Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S, 2022) |
| "Morphine has been found to elevate dopamine levels, which indicates a potential therapeutic effect in PD treatment that has not been investigated previously." | 1.40 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. ( Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S, 2014) |
| "The development of Parkinson's disease is accompanied by concurrent activation of caspase-3 and apoptosis of dopaminergic neurons of human patients and rodent models." | 1.36 | Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. ( Amutuhaire, W; Ichinose, F; Kaneki, M; Kida, K; Yamada, M, 2010) |
| "The dynamics of hypokinesia in male C57Bl/6 mice induced by single administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was studied on the model of parkinsonian syndrome." | 1.35 | Relationship between the severity of hypokinesia induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and neurochemical changes in brain structures of C57Bl/6 mice. ( Kalinina, TS; Kapitza, IG; Klodt, PM; Kudrin, VS; Narkevich, VB; Nerobkova, LN; Voronina, TA, 2008) |
| " A significant reduction of the ligand-DATs binding was found in the mice treated with MPTP, but not with TIQ, under the dosage inducing behavioral abnormality and loss of tyrosine hydroxylase-positive cells in the substantia nigra." | 1.31 | Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum. ( Abe, K; Ishiwata, K; Kawamura, K; Koyanagi, Y; Saitoh, T; Sano, T; Senda, M; Taguchi, K; Toda, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Pal Roy, S | 1 |
| Kadiri, SK | 1 |
| Karkar, VV | 1 |
| Rao Konijeti, S | 1 |
| Qiao, CM | 1 |
| Sun, MF | 1 |
| Jia, XB | 1 |
| Li, Y | 1 |
| Zhang, BP | 1 |
| Zhao, LP | 1 |
| Shi, Y | 1 |
| Zhou, ZL | 1 |
| Zhu, YL | 1 |
| Cui, C | 1 |
| Shen, YQ | 1 |
| Kucheryanu, VG | 1 |
| Vetrile, LA | 1 |
| Zakharova, IA | 1 |
| Voronina, NA | 1 |
| Yan, T | 1 |
| Rizak, JD | 1 |
| Yang, S | 1 |
| Li, H | 1 |
| Huang, B | 1 |
| Ma, Y | 1 |
| Hu, X | 1 |
| Viana, SD | 1 |
| Fernandes, RC | 1 |
| Canas, PM | 1 |
| Silva, AM | 1 |
| Carvalho, F | 1 |
| Ali, SF | 1 |
| Fontes Ribeiro, CA | 1 |
| Pereira, FC | 1 |
| Kapitza, IG | 1 |
| Kalinina, TS | 1 |
| Nerobkova, LN | 1 |
| Voronina, TA | 1 |
| Klodt, PM | 1 |
| Narkevich, VB | 1 |
| Kudrin, VS | 1 |
| Yamada, M | 1 |
| Kida, K | 1 |
| Amutuhaire, W | 1 |
| Ichinose, F | 1 |
| Kaneki, M | 1 |
| Tasaki, Y | 1 |
| Yamamoto, J | 1 |
| Omura, T | 1 |
| Sakaguchi, T | 1 |
| Kimura, N | 1 |
| Ohtaki, K | 1 |
| Ono, T | 1 |
| Suno, M | 1 |
| Asari, M | 1 |
| Ohkubo, T | 1 |
| Noda, T | 1 |
| Awaya, T | 1 |
| Shimizu, K | 1 |
| Matsubara, K | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Beal, MF | 1 |
| Fredriksson, A | 1 |
| Eriksson, P | 1 |
| Archer, T | 1 |
| Shiozaki, S | 1 |
| Ichikawa, S | 1 |
| Nakamura, J | 1 |
| Kitamura, S | 1 |
| Yamada, K | 1 |
| Kuwana, Y | 1 |
| Henry, B | 1 |
| Fox, SH | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Ishiwata, K | 1 |
| Koyanagi, Y | 1 |
| Abe, K | 1 |
| Kawamura, K | 1 |
| Taguchi, K | 1 |
| Saitoh, T | 1 |
| Toda, J | 1 |
| Senda, M | 1 |
| Sano, T | 1 |
| Baron, MS | 1 |
| Wichmann, T | 1 |
| Ma, D | 1 |
| DeLong, MR | 1 |
14 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Bradykinesia
| Article | Year |
|---|---|
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antipar | 2022 |
Sodium Butyrate Exacerbates Parkinson's Disease by Aggravating Neuroinflammation and Colonic Inflammation in MPTP-Induced Mice Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Butyric Acid; Cell Line; Colon; C | 2020 |
Effect of Anti-Glutamate Antibodies in Modeled Parkinsonian Syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Antibodies; Antip | 2020 |
Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Hypokinesia; Levodopa; Maca | 2014 |
Presymptomatic MPTP Mice Show Neurotrophic S100B/mRAGE Striatal Levels.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehydes; Animals; Corpus Striatum; Disease Models, A | 2016 |
Relationship between the severity of hypokinesia induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and neurochemical changes in brain structures of C57Bl/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Hypokinesia; Male; Mice; Mic | 2008 |
Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Disease Models, Animal; | 2010 |
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Beha | 2012 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cyclic N-Oxides; Dopami | 1997 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychoti | 1999 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Ther | 2001 |
Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding, Competitive; Corpus Striatum; Diseas | 2001 |
Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Disease | 2002 |